Q-omics provides the consensus-scored NKILA profile across patient tissues and cancer cell-line models. NKILA expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, NKILA is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, NKILA RNA expression shows 16,608 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight CESC, HNSC, and KIRP as cancer lineages where NKILA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKILA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKILA survival associations across molecular data types. NKILA RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKILA RNA expression–survival associations across cancer types. High NKILA expression shows unfavorable associations in CESC, LUSC, KIRC, ACC and COAD, but favorable associations in UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for NKILA RNA expression.
This table summarizes NKILA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NKILA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKILA shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LUAD, BLCA and COAD. The HNSC box plot shows higher NKILA RNA expression in tumor versus normal tissue (log2 FC = +1.116, t-test p < 0.001).
This table shows molecular features associated with NKILA in patient tissues and cancer cell lines. In patient samples, NKILA shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
